39 results
SC 14D9/A
KNTE
Kinnate Biopharma Inc
22 Mar 24
Tender offer solicitation (amended)
5:14pm
strategy, and instructed the Company’s management to seek to maintain asset value in order to continue to pursue a potential Exarafenib partnership
SC 14D9
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
in its decision-making by, the Kinnate Board. The Kinnate Board decided to maintain flexibility in its strategy, and instructed the Company’s management
8-K
KNTE
Kinnate Biopharma Inc
16 Jan 24
Regulation FD Disclosure
4:05pm
, results of operations, business strategy and financial needs. Actual events, trends or results could differ materially from the plans, intentions
8-K
KNTE
Kinnate Biopharma Inc
15 Nov 23
Other Events
9:00am
and trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Actual events
8-K
EX-99.1
75o2fb5
18 Sep 23
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
4:28pm
8-K
63yuzqif8u52w8ps4
18 Sep 23
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
4:28pm
8-K
EX-99.1
olv 6rbqvayzoz2g34x8
11 May 23
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates
4:15pm
8-K
EX-99.2
6ay5f qj1
17 Apr 23
Results of Operations and Financial Condition
3:15pm
8-K
sd1iq5w dz
17 Apr 23
Results of Operations and Financial Condition
3:15pm
8-K
EX-99.1
uz0p zb5j
17 Apr 23
Results of Operations and Financial Condition
3:15pm
POS AM
fkvte2ba9p79xzbk4i1n
28 Mar 22
Prospectus update (post-effective amendment)
5:23pm